Böhm W, Mertens T, Schirmbeck R, Reimann J
Institute of Medical Microbiology, University of Ulm, Germany.
Vaccine. 1998 May-Jun;16(9-10):949-54. doi: 10.1016/s0264-410x(97)00302-2.
Induction of humoral and MHC (major histocompatibility complex)-I-restricted, cytotoxic T lymphocyte (CTL) responses of Balb/c mice to the small hepatitis B surface antigen (HBsAg) were studied with a protein antigen or a DNA vaccine. Different routes were used to deliver the HBsAg-encoding plasmid DNA or the recombinant HBsAg particles: different doses of expression plasmid DNA (10 micrograms or 100 micrograms per mouse) or of recombinant HBsAg lipoprotein particles were injected into different (normal or regenerating) muscles (m. tibialis anterior and m. quadriceps), into subcutaneous tissue (at the base of the tail), into the peritoneal cavity, or intravenously (into the tail vein). At different time points post-vaccination, the induction of HBsAg specific, MHC-I-restricted CD8+ T cells and of serum antibodies to HBsAg was monitored. The data show that the intramuscular and subcutaneous but not the intravenous and intraperitoneal injection of 'naked' DNA efficiently and reliably primes cellular and humoral immune responses. In contrast, recombinant HBsAg particles injected by all four routes (without adjuvants) efficiently primed specific humoral and CTL responses. These data demonstrate that the choice of routes to deliver 'naked' plasmid DNA for obtaining efficacious immunogenicity of the expressed antigen is restricted.
用蛋白质抗原或DNA疫苗研究了Balb/c小鼠对小乙肝表面抗原(HBsAg)的体液免疫及MHC(主要组织相容性复合体)-I限制的细胞毒性T淋巴细胞(CTL)反应。采用不同途径递送编码HBsAg的质粒DNA或重组HBsAg颗粒:将不同剂量的表达质粒DNA(每只小鼠10微克或100微克)或重组HBsAg脂蛋白颗粒注射到不同(正常或再生)肌肉(胫前肌和股四头肌)、皮下组织(尾基部)、腹腔或静脉内(尾静脉)。在接种疫苗后的不同时间点,监测HBsAg特异性、MHC-I限制的CD8+T细胞的诱导情况以及血清中抗HBsAg抗体的产生情况。数据表明,肌肉内和皮下注射“裸”DNA能有效且可靠地引发细胞免疫和体液免疫反应,而静脉内和腹腔内注射则不能。相比之下,通过所有四种途径(无佐剂)注射的重组HBsAg颗粒能有效引发特异性体液免疫和CTL反应。这些数据表明,为使表达的抗原获得有效的免疫原性而选择递送“裸”质粒DNA的途径是有限的。